A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (Anti-PDGFBB pegylated aptamer) administered in combination with Avastin compared to Avastin monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Trial Profile

A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (Anti-PDGFBB pegylated aptamer) administered in combination with Avastin compared to Avastin monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Bevacizumab
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 27 Apr 2017 Status changed from recruiting to discontinued.
    • 01 Feb 2017 This trial has been discontinued in Netherlands as per European Clinical Trials Database record.
    • 13 Jan 2017 This trial has been discontinued in Crotia as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top